Metabolic and bariatric surgery achieves 70% steatohepatitis remission in patients with MAFLDBariatric surgery shows significant improvements for liver disease and diabetes

This meta-analysis evaluated the impact of metabolic and bariatric surgery on patients with metabolic dysfunction-associated fatty liver disease (MAFLD). The study population consisted of 71,904 patients who had biopsy-confirmed or elastography-confirmed MAFLD. The analysis included various surgical interventions, including sleeve gastrectomy, Roux-en-Y gastric bypass, and other metabolic procedures, to determine their efficacy in improving hepatic and endocrine outcomes.

The primary outcomes measured were steatohepatitis remission, fibrosis remission, and type 2 diabetes remission. The results indicated a 70% rate of steatohepatitis remission following surgery. Furthermore, the study reported a 57% rate of fibrosis remission and a 59% rate of type 2 diabetes remission. These findings suggest that surgical intervention provides significant improvements across multiple metabolic and hepatic markers for patients with MAFLD.

Secondary outcomes included assessments of postoperative complications, incretin signaling, and insulin sensitivity. While the primary outcomes showed clear improvement, the data suggests that specific mechanisms such as enhanced incretin signaling may contribute to these results. The study noted that sleeve gastrectomy and Roux-en-Y gastric bypass achieved comparable benefits in this patient population.

Safety and tolerability findings indicated an overall acceptable safety profile for appropriate candidates. However, 15% of patients experienced postoperative complications, with 4% experiencing major complications. The analysis highlighted that morbidity is higher in patients with decompensated cirrhosis or those with impaired hepatic reserve. These results underscore the importance of selecting appropriate surgical candidates based on liver health.

These findings align with established trends in bariatric surgery for metabolic disorders but specifically highlight the high rates of remission for MAFLD and type 2 diabetes. The data confirms that while surgery is effective, it is not universally applicable to all patients with advanced liver disease. For example, the study notes that endocrine instability, such as uncontrolled diabetes or thyroid dysfunction, acts as a relative contraindication.

Methodological limitations include the identification of higher risks and limited benefits in specific subgroups, namely those with portal hypertension or impaired hepatic reserve. The results are also influenced by the inherent differences in patient baseline characteristics across various surgical techniques, though sleeve gastrectomy and Roux-en-Y gastric bypass were found to be comparable.

Clinical implications suggest that bariatric surgery provides substantial benefits for MAFLD patients. Clinicians should perform thorough preoperative evaluations focusing on liver staging and endocrine stability. Patients with decompensated cirrhosis or significant portal hypertension require more cautious management due to higher morbidity risks. Questions remain regarding the long-term durability of these remission rates and the specific impact of different surgical techniques on varying degrees of fibrosis.

In summary, metabolic and bariatric surgery is a potent intervention for MAFLD, achieving high rates of steatohepatitis and diabetes remission. However, clinical decision-making must be guided by careful patient selection to mitigate risks associated with advanced liver disease or endocrine instability.